Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU)

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.

Biochemical pharmacology·2010

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Annals of oncology : official journal of the European Society for Medical Oncology·2007

Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2003

Complementary, alternative, integrative, or unconventional medicine?

The oncologist·2001

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

Cancer·2001

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Cancer·2026

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.

Cancer·2026

The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023.

Cancer·2026

Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion.

Cancer·2026

Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026.

Cancer·2026

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

Cancer·2026

First Report on the Phytochemical and Pharmacological Properties of Hedysarum yilmazunalii.

Chemistry & biodiversity·2026

Pharmacognostic profiling of Bridelia ovata leaves and evaluation of signal transducer and activator of transcription 3-mediated antiproliferative effects in triple-negative breast cancer.

Journal of advanced pharmaceutical technology & research·2026

Molecular mechanisms of traditional Chinese medicine in skin aging: a narrative review.

Frontiers in pharmacology·2026

Metyrapone in the Management of Severe Hypercortisolism Secondary to Ectopic Cushing's Syndrome.

Case reports in endocrinology·2026

Simvastatin as an immunomodulator and anti-myeloma agent - epidemiological, in vitro and murine model studies.

Frontiers in immunology·2026

The Silent Valve Culprit: A Case Report and Literature Review of Isolated Cabergoline-Induced Mitral Regurgitation.

Cureus·2026

Related Experiment Videos

Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU)

Related Concept Videos

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.

Complementary, alternative, integrative, or unconventional medicine?

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.

The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023.

Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion.

Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026.

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

First Report on the Phytochemical and Pharmacological Properties of Hedysarum yilmazunalii.

Pharmacognostic profiling of Bridelia ovata leaves and evaluation of signal transducer and activator of transcription 3-mediated antiproliferative effects in triple-negative breast cancer.

Molecular mechanisms of traditional Chinese medicine in skin aging: a narrative review.

Metyrapone in the Management of Severe Hypercortisolism Secondary to Ectopic Cushing's Syndrome.

Simvastatin as an immunomodulator and anti-myeloma agent - epidemiological, in vitro and murine model studies.

The Silent Valve Culprit: A Case Report and Literature Review of Isolated Cabergoline-Induced Mitral Regurgitation.

Related Experiment Videos

Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU)

Related Concept Videos

Related Articles